Harrow (HROW) Misses Q4 Earnings Estimates

Company Performance - Harrow (HROW) reported quarterly earnings of $0.26 per share, missing the Zacks Consensus Estimate of $0.40 per share, representing an earnings surprise of -34.46% [1] - The company posted revenues of $89.09 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.33%, compared to year-ago revenues of $66.83 million [2] - Over the last four quarters, Harrow has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once [2] Stock Outlook - Harrow shares have increased by approximately 10.6% since the beginning of the year, outperforming the S&P 500's gain of 0.5% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.11 on revenues of $68.86 million, and for the current fiscal year, it is $1.30 on revenues of $406.25 million [7] - The estimate revisions trend for Harrow was unfavorable ahead of the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical - Drugs industry, to which Harrow belongs, is currently in the bottom 43% of over 250 Zacks industries, suggesting that the outlook for the industry can significantly impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]